Neil Woodford has returned 16 months after the collapse of Woodford Investment Management with the launch of a new investment firm, which is working alongside Acacia Research to “advise” on an illiquid and unlisted portfolio of life sciences companies once owned by the Woodford Equity Income fund (WEIF).
Woodford will serve as CIO of WCM Partners, which will be based in Buckinghamshire and Jersey, serving institutional and high-net-worth investors. Woodford investors potentially in limbo for further 12 months The Acacia life sciences assets were part of "Portfolio B" in the WEIF liquidation process, with a £223.9m agreement struck between the firm and specialist broker PJT Park Hill in June to package up 19 assets, including Theravance Biopharma, Oxford Nanopore and Rutherford Health. WCM said in a statement that the assets "will form the cornerstone of a new strategy to rebuild th...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
